Dr. Andrew Pecora, chief innovation officer at Hackensack Meridian Health and founder of Children’s Organ Transplant Association, became the first practicing physician to be awarded the Dr. Sol J. Barer award from biopharmaceutical industry trade group BioNJ.
The award, which has always been given to CEOs of biopharma companies in New Jersey, is named after the founder and former CEO of Celgene Corp. and was given to Pecora for his innovations in value-based health care and health care administration, and for his expertise and innovation in stem cell transplantation, cellular medicine and immunology research.
“I am extremely honored and humbled to receive the Sol J. Barer award for vision, innovation and leadership from BioNJ, considering the accomplishments of the awards namesake and all of the other prior distinguished awardees,” said Pecora in his acceptance speech. “… Tonight, on its 25th anniversary, BioNJ has convened all of us to accelerate our collective mission to have New Jersey, lead our nation and the world in innovation to find more cures and relieve more suffering because patients can’t wait.”
Debbie Hart, BioNJ’s president, presented Pecora with the award during BioNJ’s 25th anniversary gala and awards ceremony Feb. 1 in New Brunswick.
In her remarks, Hart said New Jersey’s biopharma industry made great strides in 2017 with the introduction of groundbreaking new and medications and treatment therapies.
“We look forward to a bright future in 2018 and beyond,” she said.
BioNJ awarded 26 biopharma companies for introducing new drugs and treatments in 2017 for a vast array of diseases and conditions, including cancer, diabetes, irritable bowel syndrome and hepatitis. Those companies are:
|PTC Therapeutics Inc.|
|Symbiomix Therapeutics LLC|